++++"Well, Bavi is still early in human clinical studies. PPHM will have to present strong human efficacy and safety data to BP proving such....and convince patients that Bavi IV treatment is superior or equal to the investigational nukes that are being partnered this early."
That is correct mskso, but the unique and novel MOA of Bavi AV will draw attention the further and deeper that it gets into trials especially with the likes of Drs. McHutchison and Godofsky on board with the SRB and conducting the clinical trial for HCV at the Bach and Godofsky Center here in Sarasota Florida, where I reside as you well know.
I know that you follow all the comings and goings in biotech and are accutely attuned to the HCV trials and what do you see the effects of the Protease and Integrase Inhibitors trials on an HCV cure vs the potential for Bavi AV, once she passes her many hurdles ahead? I see that Bavi AV will be the successor to Interferon without all the bad side effects and toxicity issues that pervade the HCV boards daily.
Also, the infusion issue will be something that I am sure that PPHM will be seeking alternatives to, but VX-950 and it thrice a day pill intake or else the viral rebound effect is not much of a great answer either. Coley, IDIX and all the other Protease and Proteome Inhibitor stocks will have to deal with their own optimal infusion issues as well. So far, the Bavi AV IV infusion situation has not been a problem due to the small trial population, but could once the protocol gets expanded and the FDA wants a better method of application or at least a different one. Thanks for the response and post your thoughts when you can.
Peace,
Market Data 
Markets 
AI
